Allogene Therapeutics, Inc. (ALLO) Financial Ratios
9 years of historical data (2017–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
1.71
↑+31% vs avg
5yr avg: 1.31
30Y Low1.0·High4.2
ROE
↓
-53.4%
-19% vs avg
5yr avg: -45.0%
30Y Low-60%·High-18%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
ALLO Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Allogene Therapeutics, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $521M | $302M | $415M | $504M | $900M | $2.0B | $3.0B | $2.6B | $2.4B | — |
| Enterprise Value | $544M | $326M | $430M | $516M | $940M | $1.9B | $2.9B | $2.5B | $1.7B | — |
| P/E Ratio → | -2.61 | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | 18861.34 | 5302.65 | 5771.76 | 17.76 | — | — | — | — |
| P/B Ratio | 1.71 | 1.03 | 0.98 | 0.98 | 1.35 | 2.19 | 2.81 | 4.17 | 3.43 | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
ALLO EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | 19567.62 | 5428.61 | 6023.17 | 16.88 | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — |
ALLO Profitability
Margins and return-on-capital ratios measuring operating efficiency
Operating margins have compressed from -344986.3% to -1241813.6% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -53.4% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | 100.0% | 100.0% | -9063.5% | 100.0% | — | — | — | — |
| Operating Margin | — | — | -1241813.6% | -344986.3% | -215087.2% | -157.9% | — | — | — | — |
| Net Profit Margin | — | — | -1170863.6% | -344489.5% | -218214.1% | -159.6% | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -53.4% | -53.4% | -55.1% | -55.5% | -42.8% | -18.2% | -29.3% | -27.7% | -60.2% | — |
| ROA | -39.6% | -39.6% | -43.2% | -44.7% | -36.4% | -16.0% | -25.7% | -24.8% | -27.3% | — |
| ROIC | -41.7% | -41.7% | -42.6% | -40.0% | -32.9% | -15.2% | -26.6% | -57.9% | -1778.1% | — |
| ROCE | -46.7% | -46.7% | -48.8% | -47.7% | -37.9% | -16.9% | -28.4% | -28.3% | -25.4% | — |
ALLO Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $23M ($75M total debt minus $52M cash).
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.26 | 0.26 | 0.21 | 0.19 | 0.15 | 0.08 | 0.05 | 0.08 | 0.05 | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | 0.08 | 0.04 | 0.02 | 0.06 | -0.11 | -0.12 | -0.19 | -0.98 | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | 0.00 |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | -1509.39 | — | — | — | — | — | -57.43 | — |
ALLO Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Allogene Therapeutics, Inc.'s current ratio of 7.93x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 12.38x to 7.93x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 7.93 | 7.93 | 8.54 | 12.38 | 9.84 | 9.84 | 8.96 | 16.46 | 15.89 | — |
| Quick Ratio | 7.93 | 7.93 | 8.54 | 12.38 | 9.84 | 9.84 | 8.96 | 16.46 | 24.78 | — |
| Cash Ratio | 7.70 | 7.70 | 8.23 | 12.10 | 9.63 | 9.55 | 8.78 | 16.04 | 24.49 | — |
| Asset Turnover | — | — | 0.00 | 0.00 | 0.00 | 0.11 | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | 31522.73 | 6531.58 | — | — | — | — | — | — |
ALLO Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Allogene Therapeutics, Inc. returns 0.2% to shareholders annually primarily through share buybacks.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.2% | 0.3% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Total Shareholder Yield | 0.2% | 0.3% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Shares Outstanding | — | $221M | $195M | $157M | $143M | $136M | $120M | $101M | $90M | $44M |
Peer Comparison
Compare ALLO with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 ALLOYou | $521M | -2.6 | — | — | — | — | -53.4% | -41.7% | — |
 CRSP | $5B | -8.1 | — | — | -6537.0% | -16191.4% | -30.2% | -22.3% | — |
 FATE | $280M | -2.1 | — | — | — | -2222.4% | -51.8% | -36.5% | — |
 BEAM | $3B | -38.9 | — | — | 84.0% | -274.6% | -8.1% | -31.1% | — |
 NTLA | $2B | -3.6 | — | — | 76.5% | -651.7% | -53.5% | -44.0% | — |
 EDIT | $297M | -1.7 | — | — | — | — | -198.1% | — | — |
 CELH | $9B | 137.0 | 18.2 | 27.2 | 50.4% | 18.6% | 5.2% | 19.7% | 1.3 |
 CABA | $409M | -2.4 | — | — | — | — | -127.0% | -429.6% | — |
 IMVT | $6B | -10.0 | — | — | — | — | -62.5% | — | — |
 NKTR | $2B | -8.6 | — | — | 100.0% | -236.8% | -217.9% | -57.2% | — |
 AUTL | $410M | -1.8 | — | — | -1293.5% | -2385.6% | -81.9% | -204.1% | — |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 9 years · Updated daily
See ALLO's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ALLO Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ALLO vs CRSP
Side-by-side business, growth, and profitability comparison vs CRISPR Therapeutics AG.
Start ComparisonALLO — Frequently Asked Questions
Quick answers to the most common questions about buying ALLO stock.
What is Allogene Therapeutics, Inc.'s P/E ratio?
Allogene Therapeutics, Inc.'s current P/E ratio is -2.6x. This places it at the 50th percentile of its historical range.
What is Allogene Therapeutics, Inc.'s ROE?
Allogene Therapeutics, Inc.'s return on equity (ROE) is -53.4%. The historical average is -42.8%.
Is ALLO stock overvalued?
Based on historical data, Allogene Therapeutics, Inc. is trading at a P/E of -2.6x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.